Histological changes in the colonic mucosa following irrigation with short-chain fatty acids

Eur J Gastroenterol Hepatol. 1997 Feb;9(2):163-8. doi: 10.1097/00042737-199702000-00010.

Abstract

Objectives: Short-chain fatty acids (SCFAs) derived from bacterial fermentation of complex carbohydrates are preferred luminal nutrients of the colonic mucosa. Starvation of colonocytes through lack or impaired metabolism of luminal SCFAs may be a cofactor in the pathogenesis of ulcerative colitis.

Design: A detailed histological evaluation of colonic biopsy specimens was performed in patients with active distal ulcerative colitis who were treated with rectal enemas containing a mixture of SCFAs, n-butyrate alone or saline placebo. Together with light microscopic parameters of mucosal inflammation, the pattern of crypt cell proliferation (proliferating cell nuclear antigen) and the mucosal activity of factor XIII were assessed.

Results: Butyrate reduced the density of polymorphonuclear leucocytes in the lamina propria (4 weeks: P = 0.063; 8 weeks: P = 0.091); other inflammatory parameters remained unchanged. Both butyrate and the SCFA mixture reduced significantly the number of proliferating cells in the upper 40% of crypts. Tissue factor XIII activity in active ulcerative colitis was significantly lower than in mucosa from normal colons; however, it was not affected by SCFA or butyrate irrigation.

Conclusion: SCFAs and butyrate have a more marked effect on crypt cell proliferation than on parameters of inflammation in patients with active ulcerative colitis.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Biopsy
  • Butyrates / administration & dosage
  • Butyrates / therapeutic use
  • Butyric Acid
  • Colitis, Ulcerative / metabolism
  • Colitis, Ulcerative / pathology
  • Colitis, Ulcerative / therapy*
  • Enema
  • Factor XIII / metabolism
  • Fatty Acids, Volatile / administration & dosage
  • Fatty Acids, Volatile / pharmacology
  • Fatty Acids, Volatile / therapeutic use*
  • Female
  • Humans
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / pathology*
  • Male
  • Middle Aged
  • Proliferating Cell Nuclear Antigen / metabolism
  • Treatment Outcome

Substances

  • Butyrates
  • Fatty Acids, Volatile
  • Proliferating Cell Nuclear Antigen
  • Butyric Acid
  • Factor XIII